Rebecca R. (Hermes) Carrizosa


  • JD, with Honors, University of Texas School of Law, 2007; Order of the Coif; Texas Law Review
  • BA (Economics), with Honors, cum laude, Williams College, 2000


  • California, 2007

Court Admissions

  • U.S. District Court for the Northern District of California, 2011
  • U.S. District Court for the Central District of California, 2011
  • Becky teaches a mock trial legal apprenticeship to students from a local middle school through the Citizen Schools extended learning time program.

Rebecca R. (Hermes) Carrizosa


Becky Carrizosa is a trial attorney and experienced litigator in Ropes & Gray’s intellectual property group, focusing primarily on patent litigation. Becky has extensive experience in all stages of litigation, from pre-suit investigation and discovery through jury trial and appeal. At trial, Becky has argued motions and conducted direct and cross-examinations of fact and expert witnesses. Becky’s trial experience includes three bench trials and four jury trials in federal courts.

Becky represents clients from diverse industries, including pharmaceuticals, semiconductors, consumer electronics, and software. She works closely with clients to develop cost-effective and successful litigation strategies.

Prior to attending law school, Becky worked for Charles River Associates in Boston, Massachusetts. Becky supported expert witnesses in litigation and regulatory matters by performing quantitative and statistical analyses.


  • Rembrandt Wireless Technologies LP v. Samsung Electronics et al. and Imperium IP Holdings (Cayman), Ltd. v. Samsung Electronics (E.D. Tex.) (E.D. Tex.): Defending Samsung Electronics in two patent infringement actions, each of which involved week-long jury trials.
  • Godo Kaisha IP Bridge 1 v. Broadcom Ltd et al. (E.D. Tex.) – Representing IP Bridge in a patent infringement action involving semiconductors.
  • Purdue Pharma L.P. et al. v. Teva Pharmaceuticals USA, Inc. et al. and related cases (S.D.N.Y.): Twelve-day bench trial on six patents, three relating to abuse-deterrent reformulation of Purdue’s OxyContin® tablets, three relating to oxycodone hydrochloride active pharmaceutical ingredient having reduced levels of 14-hydroxycodeinone.
  • Purdue Pharma L.P. v. Ranbaxy Inc., Actavis Elizabeth LLC, and Mylan Pharmaceuticals, Inc., (S.D.N.Y., E.D. Pa., MDL) – Eight-day bench trial on three Purdue patents relating to oxycodone hydrochloride active pharmaceutical ingredient having reduced levels of 14-hydroxycodeinone. Action dismissed as moot, following related decision in Purdue’s favor by U.S. Food & Drug Administration.
  • Eolas v. Adobe et al(E.D. Tex.): Represented defendants Google Inc. and YouTube, LLC in securing victory in a case brought by Eolas Technologies Inc. on two patents that it contended cover all web sites containing interactive content. After a four-day invalidity trial involving multiple defendants, an Eastern District of Texas jury returned a verdict that all asserted claims of both patents are invalid.
  • OPTi, Inc. v. Advanced Micro Devices, Inc. (E.D. Tex.): Five-day jury trial on OPTi’s patent relating to core-logic chipsets. The action settled during trial, shortly before it would have been submitted to the jury. 



  • Speaker, "Patent Damages: New Rules, New Tools," Ropes & Gray CLE Seminar, September 2011
Cookie Settings